Efficacy, Tolerability, and Safety of Fluoxetine for Panic Disorder in Adults: A Review.
- 1Counselling Psychology, Yorkville University, Fredericton, CAN.
- 2Counselling Psychology, University of Alberta, Edmonton, CAN.
- 3Pharmacology, Chitkara University, Patiala, IND.
Abstract
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used in the pharmacological treatment of panic disorder. Its efficacy is supported by clinical trials, but the response to treatment and tolerability vary between patients, driving interest in strategies that could improve its clinical use. This review evaluates the effectiveness and side effects of fluoxetine in panic disorder, discusses clinical, pharmacokinetic, and pharmaceutical barriers to treatment, and assesses current and emerging strategies for treatment optimization. We conducted a structured literature review drawing on two complementary streams of evidence. We reviewed the clinical literature for evidence of fluoxetine efficacy, response, remission, maintenance, adverse effects, tolerability, and discontinuation in panic disorder. A second stream was dedicated to fluoxetine-specific research on pharmacokinetics, pharmacogenetics, formulations, and drug delivery. Clinical conclusions were based on randomized controlled trials and systematic reviews, whereas preclinical and physicochemical investigations were separately addressed as potential future approaches. Randomized trials support the efficacy of fluoxetine for panic disorder across panic symptoms, anxiety, phobic symptoms, global improvement, and functioning. Placebo-controlled evidence suggests that fluoxetine may increase the likelihood of achieving panic-free status during treatment. Fluoxetine has generally been well tolerated in controlled studies, although early activation, gastrointestinal effects, insomnia, and treatment intolerance were noted in some patients. Cytochrome P450 2D6 (CYP2D6) contributes to variability in fluoxetine and norfluoxetine concentrations, but there is insufficient evidence to support the routine use of genotype to guide dosing. Cocrystals, nanoparticles, and intranasal delivery systems can alter physicochemical properties or drug distribution but have not been demonstrated to be clinically helpful in panic disorder. Fluoxetine is a pharmacological option with evidence of efficacy in panic disorder. The clinical value of fluoxetine depends on a balance between efficacy and tolerability. Optimization now should focus on individualized initiation and titration of doses, management of adverse effects, adherence, drug interactions, patient preferences, and ongoing monitoring. Pharmacogenetics, therapeutic drug monitoring, and advanced drug delivery systems are still promising areas of investigation for the future rather than established clinical strategies.
Related
- Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus Mpro Inhibitor, in Healthy Adults: A Randomized, Single- and Multiple-Dose Study.
- Stroboscopic Light Stimulation in Adults Reporting Depressive Symptoms: Safety, Tolerability, Feasibility, and Active-Comparator Development in a Staged Early-Phase Study
- Short-term safety and local tolerability of repeated exposure to aerosolized hypochlorous acid dry fog in healthy adults: a randomized controlled pilot study
- Efficacy and safety of long-acting injectable aripiprazole in bipolar disorder: a multinational real-world target trial emulation
- Comparative efficacy and safety of targeted disease-modifying therapies in adults with primary IgA nephropathy: a systematic review and network meta-analysis
BibTeX
@article{mohammad2026efficacy,
title = {{Efficacy, Tolerability, and Safety of Fluoxetine for Panic Disorder in Adults: A Review.}},
author = {Haseeb Mohammad and Sehasbir Singh and Inderbir Singh},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116516},
url = {https://europepmc.org/article/MED/42898501},
note = {CC BY},
}
RIS
TY - JOUR
TI - Efficacy, Tolerability, and Safety of Fluoxetine for Panic Disorder in Adults: A Review.
AU - Haseeb Mohammad
AU - Sehasbir Singh
AU - Inderbir Singh
PY - 2026
DA - 2026/09/18
JO - Cureus
DO - 10.7759/cureus.116516
UR - https://europepmc.org/article/MED/42898501
AB - Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used in the pharmacological treatment of panic disorder. Its efficacy is supported by clinical trials, but the response to treatment and tolerability vary between patients, driving interest in strategies that could improve its clinical use. This review evaluates the effectiveness and side effects of fluoxetine in panic disorder, discusses clinical, pharmacokinetic, and pharmaceutical barriers to treatment, and assesses current and emerging strategies for treatment optimization. We conducted a structured literature review drawing on two complementary streams of evidence. We reviewed the clinical literature for evidence of fluoxetine efficacy, response, remission, maintenance, adverse effects, tolerability, and discontinuation in panic disorder. A second stream was dedicated to fluoxetine-specific research on pharmacokinetics, pharmacogenetics, formulations, and drug delivery. Clinical conclusions were based on randomized controlled trials and systematic reviews, whereas preclinical and physicochemical investigations were separately addressed as potential future approaches. Randomized trials support the efficacy of fluoxetine for panic disorder across panic symptoms, anxiety, phobic symptoms, global improvement, and functioning. Placebo-controlled evidence suggests that fluoxetine may increase the likelihood of achieving panic-free status during treatment. Fluoxetine has generally been well tolerated in controlled studies, although early activation, gastrointestinal effects, insomnia, and treatment intolerance were noted in some patients. Cytochrome P450 2D6 (CYP2D6) contributes to variability in fluoxetine and norfluoxetine concentrations, but there is insufficient evidence to support the routine use of genotype to guide dosing. Cocrystals, nanoparticles, and intranasal delivery systems can alter physicochemical properties or drug distribution but have not been demonstrated to be clinically helpful in panic disorder. Fluoxetine is a pharmacological option with evidence of efficacy in panic disorder. The clinical value of fluoxetine depends on a balance between efficacy and tolerability. Optimization now should focus on individualized initiation and titration of doses, management of adverse effects, adherence, drug interactions, patient preferences, and ongoing monitoring. Pharmacogenetics, therapeutic drug monitoring, and advanced drug delivery systems are still promising areas of investigation for the future rather than established clinical strategies.
SN - 2168-8184
ER -